Pre-Transplant Frequencies of FoxP3+CD25+ in CD3+CD8+ T Cells as Potential Predictors for CMV in CMV-Intermediate Risk Kidney Transplant Recipients
Transplant International · 2024
DOI: 10.3389/ti.2024.12963 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2024. Verfasst von Agnes A Mooslechner und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. Hauptthemen laut MEDLINE: Kidney Transplantation, Cytomegalovirus Infections, CD8-Positive T-Lymphocytes, Forkhead Transcription Factors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cytomegalovirus (CMV) infection detrimentally influences graft survival in kidney transplant recipients, with the risk primarily determined by recipient and donor serostatus. However, recipient CD8 + T cells play a crucial role in CMV control. The optimal preventive strategy (prophylaxis vs. pre-emptive treatment), particularly for seropositive (intermediate risk) recipients, remains uncertain. We investigated CD8 + T cell subpopulation dynamics and CMV occurrence (DNAemia ≥ 100 IU/mL) in 65 kidney transplant recipients, collecting peripheral blood mononuclear cells before (T1) and 1 year after transplantation (T2). Comparing the two timepoints, we found an increase in granulocyte, monocyte and CD3 + CD8 + T cells numbers, while FoxP3 + CD25 + , LAG-3 + and PD-1 + frequencies were reduced at T2. CMV DNAemia occurred in 33 recipients (55.8%) during the first year. Intermediate risk patients were disproportionally affected by posttransplant CMV ( N = 29/45, 64.4%). Intermediate risk recipients developing CMV after transplantation exhibited lower leukocyte, monocyte, and granulocyte counts and higher FoxP3 + CD25 + frequencies in CD3 + CD8 + T cells pre-transplantation compared to patients staying CMV negative. Pre-transplant FoxP3 + CD25 + in CD3 + CD8 + T cells had the best discriminatory potential for CMV infection prediction within the first year after transplantation (AUC: 0.746). The FoxP3 + CD25 + CD3 + CD8 + T cell subset may aid in selecting intermediate risk kidney transplant recipients for CMV prophylaxis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- Otto Loewi Research Center, Division of Pharmacology, Medical University of Graz, Graz, Austria.
- Center for Biomarker Research in Medicine, CBmed GmbH, Graz, Austria.
- Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- Division of General, Visceral and Transplant Surgery, Department of Surgery, Medical University of Graz, Graz, Austria.
Zitieren
APA
Mooslechner, A. A., Schuller, M., Pfeifer, V., Klötzer, K. A., Prietl, B., Kirsch, A. H., Stiegler, P., Sucher, R., Sourij, H., Rosenkranz, A. R., & Eller, K. (2024). Pre-Transplant Frequencies of FoxP3+CD25+ in CD3+CD8+ T Cells as Potential Predictors for CMV in CMV-Intermediate Risk Kidney Transplant Recipients. Transplant International. https://doi.org/10.3389/ti.2024.12963
Vancouver
Mooslechner AA, Schuller M, Pfeifer V, Klötzer KA, Prietl B, Kirsch AH, et al. Pre-Transplant Frequencies of FoxP3+CD25+ in CD3+CD8+ T Cells as Potential Predictors for CMV in CMV-Intermediate Risk Kidney Transplant Recipients. Transplant International. 2024. doi:10.3389/ti.2024.12963
BibTeX
@article{Mooslechner2024,
author = {Mooslechner, Agnes A and Schuller, Max and Pfeifer, Verena and Klötzer, Konstantin A and Prietl, Barbara and Kirsch, Alexander H and Stiegler, Philipp and Sucher, Robert and Sourij, Harald and Rosenkranz, Alexander R and Eller, Kathrin},
title = {Pre-Transplant Frequencies of FoxP3+CD25+ in CD3+CD8+ T Cells as Potential Predictors for CMV in CMV-Intermediate Risk Kidney Transplant Recipients},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.12963}
}
EUVIMED